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ABSTRACT
Apoptosis (programmed cell death) is required for the removal of infected, 
damaged or unwanted cells. Inadequate cell death is a major contributing factor 
to tumorigenesis, while excess cell death contributes to neurodegeneration and 
autoimmune diseases.
Current investigations suggest the mechanisms by which Bcl-2 might pre-
vent cell death. Bcl-2 family members mediate anti-apoptotic signals in a wide 
variety of human cell systems. Bcl-2 protein family, through its role in the regu-
lation of apoptotic pathways, is possibly related to cancer pathophysiology. This 
review article discribes some pathways how apoptotic cell death is controlled by 
this protein family. 
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MAIN TEXT
The cells of a multicellular organism are members of a highly organized com-
munity. The number of cells in this community is tightly regulated – not sim-
ply by controlling the rate of cell division, but also by controlling the rate of 
cell death. If cells are no longer needed, they commit suicide by activating an 
intracellular death program. This process is therefore called the programmed 
cell death, although it is more commonly called apoptosis (from a Greek word 
meaning “falling off,” as leaves from a tree) [1].
Apoptosis, also called the programmed cell death (PCD), plays a key role in 
developmental biology and in the maintenance of the steady state in continu-
osly renewing tissues. The PCD is a selective process of physiological cell dele-
tion [21, 24].
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Apoptosis is characterized by two major markers. The first is composed of 
morphological features such as reduction in the cell volume, the chromatin con-
densation, and the nuclear fragmentation, resulting in apoptotic bodies. The 
other marker is DNA cleavage by a Ca2 /Mg2 – dependent endonuclease into 
oligonucleosomal-length fragments detected as a ladder pattern on gel electro-
phoresis [25].
One of the oncogenes regulating apoptosis is Bcl-2 (B-cell lymphoma 2). 
Bcl-2, encoded by the BCL2 gene, is the founding member of the Bcl-2 family 
of the regulator proteins that regulate apoptosis [3, 16].
Bcl-2 family member proteins are the anti-apoptotic molecules that are 
known to be overexpressed in most cancers. The pro-apoptotic Bcl-2 family 
members are Bax, tBid, Bak, Bax, Bik, Bok, Bim, Krk, Mtd and others. The anti-
apoptotic subfamily comprises Bcl-2, Bcl-xL, Bcl-w, Mcl-1, A1(Bfl-1), and Bcl-B.
The major function of Bcl-2 family members is to control directly mitochon-
drial membrane permeability and thereby regulate the release of apoptogenic 
factors from the intermembrane space into the cytoplasm [6, 10, 17, 18, 27]. 
Apoptogenic factors known to be released include cytochrome c, Smac Diablo 
[4], AIF [14], heat shock protein 60 [13], and endonuclease G. Smac Diablo 
and cytochrome c are involved in the activation of caspases. AIF and endo-
nuclease G are thought to play roles in the induction of caspase-independent 
apoptotic changes in nuclei. Anti-apoptotic members of the Bcl-2 family inhibit 
the release of these apoptogenic factors, whereas pro-apoptotic members pro-
mote it [19].
The “point of no return” in this pathway is defined by mitochondrial 
outer membrane permeabilization (MOMP), which leads to the release of 
cytochrome c [2]. Bcl-2 family proteins regulate MOMP and thereby deter-
mine the cellular commitment to apoptosis. From the above discussion, it is 
clear that MOMP is a greatly organized process, principally controlled through 
interactions between pro- and anti-apoptotic members of the B cell lymphoma 
2 (Bcl-2) family [15].
The intrinsic (mitochondrial) apoptotic pathway is controlled by the bal-
ance between anti-apoptotic proteins belonging to the Bcl-2 family and pro-
apoptotic proteins bearing a single BH3 domain. In healthy cells, pro-apoptotic 
proteins, Bax, Bid and Bad reside in the cytosol. On the initiation of apoptosis, 
these pro-apoptotic proteins translocate to the outer mitochondrial membrane, 
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It is well documented that Bcl-2 functions through heterodimerization 
with the proapoptotic members of the Bcl-2 family to prevent mitochondrial 
pore formation and prevent cytochrome c release and the initiation of apopto-
sis [22]. The mitochondrial (intrinsic) pathway is regulated by the Bcl-2 fam-
ily and activated by mitochondrial disruption with subsequent cytochrome 
c release. The initiators of this pathway include UV irradiation and cytotoxic 
drugs. An ‘apoptosome’ is formed by the interaction of cytochrome c, Apaf-1, 
d-ATP/ ATP and procaspase-9 with the subsequent initiation of the caspase 
cascade.
Among the investigations which are now suggesting the mechanisms by 
which Bcl-2 might prevent cell death are also the local inhibition of free radical 
production and the formation of an ionic conductance channel in membranes 
[8]. The extensive oxidative injury in ischemic neuronal death suggests that 
an antioxidant mechanism for Bcl-2 would be beneficial and might exhibit a 
greater contribution in those cases where oxidative damage is a significant com-
ponent of the cell death triggering event.
The Bcl-xL protein contains two central hydrophobic helices surrounded by 
five amphipathic helices [11], a structure similar to the pore-forming domain of 
certain bacterial toxins. Minn et al. [9] demonstrated that Bcl-xL can insert into 
membranes and form an ionic conductance channel that is cation selective at 
physiological pH. The implications for ischemia include the possibility that Bcl-
xL could regulate the sequestration of intracellular calcium that is an important 
component of the excitotoxic cell death mechanism. 
Bcl-2 related proteins form a part of the core apoptotic machinery con-
served in the species as diverse as Caenorhabditis elegans and mammals. Func-
tionally, the Bcl-2-related proteins either inhibit or promote apoptosis, and 
interaction(s) between the proteins belonging to opposing factions determines 
whether a cell lives or dies. Perhaps the best understood pathway is that in the 
worm C. elegans, where detailed genetic studies have shown that two Bcl-2 
related proteins (pro-apoptotic EGL-1 and pro-survival CED-9) are essen-
tial for controlling developmentally programmed somatic cell deaths [7]. The 
expression of EGL-1, the death trigger, is inducedby damage signals. Binding of 
EGL-1 to CED-9, the worm Bcl-2 ortholog, releases the adapter protein CED-4 
from CED-9. Once released, CED-4 binds to and activates the caspase CED-3 
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The damage to the Bcl-2 gene has been identified as a cause of a number of 
cancers, including chronic lymphocytic leukemia [12], neurodegenerative dis-
eases and autoimmunity [5]. It is also a cause of resistance to cancer treatments. 
As the knowledge about the mechanisms of Bcl-2 proteins influences on apop-
tosis, it may help develop new therapies for treating cancer, autoimmune condi-
tions, and neurological diseases. Further resarch is essential in this area. 
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